Taysha Gene Therapies (NASDAQ:TSHA) CFO Sells $375,098.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 78,968 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the sale, the chief financial officer owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. The trade was a 5.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Kamran Alam also recently made the following trade(s):

• On Monday, January 26th, Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89.

Taysha Gene Therapies Price Performance

Shares of Taysha Gene Therapies stock opened at $4.57 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The company has a market cap of $1.25 billion, a PE ratio of -13.85 and a beta of 1.02. The firm has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $4.09. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in TSHA. Vanguard Group Inc. boosted its position in Taysha Gene Therapies by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock valued at $72,973,000 after buying an additional 418,192 shares in the last quarter. Octagon Capital Advisors LP raised its stake in shares of Taysha Gene Therapies by 17.7% in the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after acquiring an additional 1,892,500 shares during the last quarter. Jefferies Financial Group Inc. boosted its holdings in shares of Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock worth $23,825,000 after acquiring an additional 10,068,479 shares in the last quarter. Vestal Point Capital LP grew its position in Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after acquiring an additional 2,500,000 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its holdings in Taysha Gene Therapies by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock valued at $17,311,000 after purchasing an additional 293,879 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on TSHA. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a research report on Thursday, December 4th. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Wells Fargo & Company increased their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.